FABP4 and metabolic disease: Recent studies using experimental models demonstrated the possibility of a new strategy for treating metabolic diseases including diabetes mellitus, atherosclerosis and vascular injury by targeting serum FABP4 with a monoclonal antibody to FABP48,11,12.